Aggressive infliximab dosing regimens – intensified induction or accelerated induction – show similar clinical responses and remission rates as the standard infliximab dosing approach in patients with ...

Restarting subcutaneous infliximab 240 mg after treatment interruption of at least 16 weeks was able to recapture response ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Please provide your email address to receive an email when new articles are posted on . Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more ...

Credit: ProciseDx The Procise ADL and Procise IFX assays can report a quantitative result within 5 minutes using a serum sample. The assays can be used to quickly assess drug levels in patients with ...

The FDA has granted a pair of de novo clearances to ProciseDx for the agency’s first rapid tests to measure the levels of specific biologic drugs within a patient’s bloodstream—allowing clinicians to ...

The European Medicines Agency (EMA) has backed the use of Celltrion Healthcare’s subcutaneous infliximab without initial intravenous loading doses. Securing the regulatory recommendation boosts ...

The US Food and Drug Administration (FDA) has approved infliximab-dyyb (Zymfentra, Celltrion USA) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn ...

Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...